BOSTON--(EON: Enhanced Online News)--Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced it will present 12-week data from TRIUMPH, a Phase 2b clinical trial of CNTX-4975 for the treatment of moderate to severe knee pain associated with osteoarthritis, at the 33rd Annual American Academy of Pain Medicine (AAPM) Meeting taking place March 16-19, 2017 at the Loews Sapphire Falls Resort in Orlando, Florida.
The study showed that treatment with CNTX-4975 resulted in rapid, large and long lasting reduction of WOMAC (Western Ontario and McMaster Universities Arthritis Index) Question A1 pain scores beginning at Week 1 and remained statistically significant through the Week 12 primary endpoint. Statistically significant improvements in knee stiffness and physical function were also seen at all time points (Weeks 4, 8 and 12) with CNTX-4975 treatment.
Full abstracts are available online at http://www.painmed.org/annualmeeting. Details of the poster presentation are listed below. Additional data from the TRIUMPH study will be presented at medical meetings later this year.
Abstract Title (#LB002): Efficacy, Safety, and Tolerability of
CNTX-4975 in Subjects with Moderate to Severe Knee Pain Associated With
Osteoarthritis: 12-Week Results of a Randomized, Double-Blind,
Placebo-Controlled, Phase 2b Study
Session Title: Late-Breaking Posters
Presentation Time: Thursday, March 16, 6–7:30 pm ET and Friday, March 17, 6–7:30 pm ET
Location: AAPM Resource Center at the Loews Sapphire Falls Resort at Universal Orlando
CNTX-4975 is based on Centrexion’s proprietary STRATI® technology (Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent, ultrapure, synthetic form of trans-capsaicin (a medicine traditionally derived from the chili plant). CNTX-4975 is designed to be injected directly into the site of pain to provide rapid onset, large reduction and long duration of relief from moderate to severe pain without affecting touch sensibility or position sense.
CNTX-4975 works by selectively targeting the capsaicin receptor (TRPV1) to rapidly inactivate only the local pain fibers transmitting signals to the brain. With a short half-life, STRATI® is cleared from the body within 24 hours. This approach provides pain relief that can last for months until the ends of the local pain fibers regenerate, while leaving the rest of the nerve fiber functioning as normal, and without the risks of toxicities of NSAIDs and injected steroids or the side effects, including abuse and addiction, associated with opioid treatments.
About Centrexion Therapeutics
Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion patients living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.
For more information about Centrexion, visit http://www.centrexion.com.